July 25, 2017
Researchers at the University of California, San Francisco have demonstrated that distinct populations of microbiota in patients with acute infection or chronic inflammatory disease are associated with distinct immune dysfunction and differences in clinical response. They have developed a method to obtain a microorganism sample and probe the microorganism population to identify diversity and plurality of microbiota.
This invention uses sequencing of microbiota community for diagnosis and treatment of lung and nasal dysbiosis.
The respiratory system hosts a large and diverse number of microorganisms, which function as a unit and are associated with human health and disease states. Distinct compositions of microbiota are associated with the development of distinct immune dysfunctions, including inflammatory bowel disease, pediatric asthma, acute pneumonia and chronic rhinosinusitus, and are also associated with significant differences in clinical outcomes. Currently, microbiota are not considered during diagnosis of lung or nasal dysbiosis. This invention identifies microbial endotypes that would benefit from differentiated therapy.
Data Availability
Under NDA/CDA
Inventors Profile
Susan Lynch, PhD http://profiles.ucsf.edu/susan.lynch
-Identify distinct populations of microbiota in patients -Develop tailored treatment based on microbiota composition
- Rapidaccess to testing results
-Relatively inexpensive testing
-Opportunity to implement precision medicine
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
respiratory system hosts
inflammatory bowel disease
distinct immune dysfunction
distinct immune dysfunctions
chronic inflammatory disease
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium